EligibleTrials

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

Recruiting · NCT07717879 · Interventional (participants receive a specific treatment) · Lead sponsor: Axsome Therapeutics, Inc.

View the official record on ClinicalTrials.gov →
ADHD

Interventions studied

PlaceboSolriamfetol Dose ASolriamfetol Dose B

What this trial is about

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \<12 years with ADHD.

Who can take part

Age range
6 Years to 11 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

23 locations listed across 14 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.